Review



natalizumab  (Biogen Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Biogen Inc natalizumab
    Forest plots representing the effect of predefined predictors on disability, assessed using the mRS at 12 months following disease onset, shown for univariate analysis (A) and multivariable ordinal regression (B). *Within the first 12 months after PML diagnosis. DMF = dimethyl fumarate; DMT = disease-modifying treatments; EDSS = Expanded Disability Status Scale; IRIS = immune reconstitution inflammatory syndrome; JCV = JC virus; mRS = modified Rankin Scale; MS = multiple sclerosis; NTZ = <t>natalizumab;</t> PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting MS; S1P-RM = sphingosine-1-phosphate receptor modulators; SPMS = secondary progressive MS.
    Natalizumab, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/natalizumab/product/Biogen Inc
    Average 86 stars, based on 1 article reviews
    natalizumab - by Bioz Stars, 2026-05
    86/100 stars

    Images

    1) Product Images from "Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments"

    Article Title: Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments

    Journal: Neurology® Neuroimmunology & Neuroinflammation

    doi: 10.1212/NXI.0000000000200558

    Forest plots representing the effect of predefined predictors on disability, assessed using the mRS at 12 months following disease onset, shown for univariate analysis (A) and multivariable ordinal regression (B). *Within the first 12 months after PML diagnosis. DMF = dimethyl fumarate; DMT = disease-modifying treatments; EDSS = Expanded Disability Status Scale; IRIS = immune reconstitution inflammatory syndrome; JCV = JC virus; mRS = modified Rankin Scale; MS = multiple sclerosis; NTZ = natalizumab; PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting MS; S1P-RM = sphingosine-1-phosphate receptor modulators; SPMS = secondary progressive MS.
    Figure Legend Snippet: Forest plots representing the effect of predefined predictors on disability, assessed using the mRS at 12 months following disease onset, shown for univariate analysis (A) and multivariable ordinal regression (B). *Within the first 12 months after PML diagnosis. DMF = dimethyl fumarate; DMT = disease-modifying treatments; EDSS = Expanded Disability Status Scale; IRIS = immune reconstitution inflammatory syndrome; JCV = JC virus; mRS = modified Rankin Scale; MS = multiple sclerosis; NTZ = natalizumab; PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting MS; S1P-RM = sphingosine-1-phosphate receptor modulators; SPMS = secondary progressive MS.

    Techniques Used: Biomarker Discovery, Virus, Modification

    Forest plots representing the effect of predefined predictors on (A) the risk of developing PML-IRIS and (B) the occurrence of recurring MS activity, based on multivariable binomial regression analysis. DMF = dimethyl fumarate; IRIS = immune reconstitution inflammatory syndrome; MS = multiple sclerosis; NTZ = natalizumab; S1P-RM = sphingosine-1-phosphate receptor modulators.
    Figure Legend Snippet: Forest plots representing the effect of predefined predictors on (A) the risk of developing PML-IRIS and (B) the occurrence of recurring MS activity, based on multivariable binomial regression analysis. DMF = dimethyl fumarate; IRIS = immune reconstitution inflammatory syndrome; MS = multiple sclerosis; NTZ = natalizumab; S1P-RM = sphingosine-1-phosphate receptor modulators.

    Techniques Used: Activity Assay



    Similar Products

    natalizumab  (Biogen Inc)
    86
    Biogen Inc natalizumab
    Forest plots representing the effect of predefined predictors on disability, assessed using the mRS at 12 months following disease onset, shown for univariate analysis (A) and multivariable ordinal regression (B). *Within the first 12 months after PML diagnosis. DMF = dimethyl fumarate; DMT = disease-modifying treatments; EDSS = Expanded Disability Status Scale; IRIS = immune reconstitution inflammatory syndrome; JCV = JC virus; mRS = modified Rankin Scale; MS = multiple sclerosis; NTZ = <t>natalizumab;</t> PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting MS; S1P-RM = sphingosine-1-phosphate receptor modulators; SPMS = secondary progressive MS.
    Natalizumab, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/natalizumab/product/Biogen Inc
    Average 86 stars, based on 1 article reviews
    natalizumab - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    natalizumab treatment  (Meira Corporation)
    86
    Meira Corporation natalizumab treatment
    Forest plots representing the effect of predefined predictors on disability, assessed using the mRS at 12 months following disease onset, shown for univariate analysis (A) and multivariable ordinal regression (B). *Within the first 12 months after PML diagnosis. DMF = dimethyl fumarate; DMT = disease-modifying treatments; EDSS = Expanded Disability Status Scale; IRIS = immune reconstitution inflammatory syndrome; JCV = JC virus; mRS = modified Rankin Scale; MS = multiple sclerosis; NTZ = <t>natalizumab;</t> PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting MS; S1P-RM = sphingosine-1-phosphate receptor modulators; SPMS = secondary progressive MS.
    Natalizumab Treatment, supplied by Meira Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/natalizumab treatment/product/Meira Corporation
    Average 86 stars, based on 1 article reviews
    natalizumab treatment - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    tysabri natalizumab  (Biogen Inc)
    86
    Biogen Inc tysabri natalizumab
    Patient pathway during the clinic visit and HCP pathway showing generic workflow for <t>natalizumab</t> IV and SC preparation and administration processes. HCP healthcare professional, IV intravenous, SC subcutaneous
    Tysabri Natalizumab, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tysabri natalizumab/product/Biogen Inc
    Average 86 stars, based on 1 article reviews
    tysabri natalizumab - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    natalizumab tysabrir  (Biogen Inc)
    86
    Biogen Inc natalizumab tysabrir
    Patient pathway during the clinic visit and HCP pathway showing generic workflow for <t>natalizumab</t> IV and SC preparation and administration processes. HCP healthcare professional, IV intravenous, SC subcutaneous
    Natalizumab Tysabrir, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/natalizumab tysabrir/product/Biogen Inc
    Average 86 stars, based on 1 article reviews
    natalizumab tysabrir - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Forest plots representing the effect of predefined predictors on disability, assessed using the mRS at 12 months following disease onset, shown for univariate analysis (A) and multivariable ordinal regression (B). *Within the first 12 months after PML diagnosis. DMF = dimethyl fumarate; DMT = disease-modifying treatments; EDSS = Expanded Disability Status Scale; IRIS = immune reconstitution inflammatory syndrome; JCV = JC virus; mRS = modified Rankin Scale; MS = multiple sclerosis; NTZ = natalizumab; PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting MS; S1P-RM = sphingosine-1-phosphate receptor modulators; SPMS = secondary progressive MS.

    Journal: Neurology® Neuroimmunology & Neuroinflammation

    Article Title: Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments

    doi: 10.1212/NXI.0000000000200558

    Figure Lengend Snippet: Forest plots representing the effect of predefined predictors on disability, assessed using the mRS at 12 months following disease onset, shown for univariate analysis (A) and multivariable ordinal regression (B). *Within the first 12 months after PML diagnosis. DMF = dimethyl fumarate; DMT = disease-modifying treatments; EDSS = Expanded Disability Status Scale; IRIS = immune reconstitution inflammatory syndrome; JCV = JC virus; mRS = modified Rankin Scale; MS = multiple sclerosis; NTZ = natalizumab; PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting MS; S1P-RM = sphingosine-1-phosphate receptor modulators; SPMS = secondary progressive MS.

    Article Snippet: As the primary cause of iatrogenic PML in multiple sclerosis (MS), natalizumab ([NTZ]–Tysabri, Biogen, Cambridge, MA) has been extensively studied over the past years.

    Techniques: Biomarker Discovery, Virus, Modification

    Forest plots representing the effect of predefined predictors on (A) the risk of developing PML-IRIS and (B) the occurrence of recurring MS activity, based on multivariable binomial regression analysis. DMF = dimethyl fumarate; IRIS = immune reconstitution inflammatory syndrome; MS = multiple sclerosis; NTZ = natalizumab; S1P-RM = sphingosine-1-phosphate receptor modulators.

    Journal: Neurology® Neuroimmunology & Neuroinflammation

    Article Title: Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments

    doi: 10.1212/NXI.0000000000200558

    Figure Lengend Snippet: Forest plots representing the effect of predefined predictors on (A) the risk of developing PML-IRIS and (B) the occurrence of recurring MS activity, based on multivariable binomial regression analysis. DMF = dimethyl fumarate; IRIS = immune reconstitution inflammatory syndrome; MS = multiple sclerosis; NTZ = natalizumab; S1P-RM = sphingosine-1-phosphate receptor modulators.

    Article Snippet: As the primary cause of iatrogenic PML in multiple sclerosis (MS), natalizumab ([NTZ]–Tysabri, Biogen, Cambridge, MA) has been extensively studied over the past years.

    Techniques: Activity Assay

    Patient pathway during the clinic visit and HCP pathway showing generic workflow for natalizumab IV and SC preparation and administration processes. HCP healthcare professional, IV intravenous, SC subcutaneous

    Journal: Neurology and Therapy

    Article Title: Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

    doi: 10.1007/s40120-026-00888-1

    Figure Lengend Snippet: Patient pathway during the clinic visit and HCP pathway showing generic workflow for natalizumab IV and SC preparation and administration processes. HCP healthcare professional, IV intravenous, SC subcutaneous

    Article Snippet: Tysabri (natalizumab), developed by Biogen, is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active RRMS.

    Techniques:

    HCP satisfaction with natalizumab preparation. HCP healthcare professional, IV intravenous, SC subcutaneous. 1 = not at all satisfied; 10 = very satisfied

    Journal: Neurology and Therapy

    Article Title: Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

    doi: 10.1007/s40120-026-00888-1

    Figure Lengend Snippet: HCP satisfaction with natalizumab preparation. HCP healthcare professional, IV intravenous, SC subcutaneous. 1 = not at all satisfied; 10 = very satisfied

    Article Snippet: Tysabri (natalizumab), developed by Biogen, is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active RRMS.

    Techniques:

    HCP satisfaction with natalizumab administration. HCP healthcare professional, IV intravenous, SC subcutaneous. 1 = not at all satisfied; 10 = very satisfied

    Journal: Neurology and Therapy

    Article Title: Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

    doi: 10.1007/s40120-026-00888-1

    Figure Lengend Snippet: HCP satisfaction with natalizumab administration. HCP healthcare professional, IV intravenous, SC subcutaneous. 1 = not at all satisfied; 10 = very satisfied

    Article Snippet: Tysabri (natalizumab), developed by Biogen, is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active RRMS.

    Techniques:

    Mean importance of reasons for preference of natalizumab SC related to preparation. SC subcutaneous. 1 = most important reason for preference; 10 = least important reason

    Journal: Neurology and Therapy

    Article Title: Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

    doi: 10.1007/s40120-026-00888-1

    Figure Lengend Snippet: Mean importance of reasons for preference of natalizumab SC related to preparation. SC subcutaneous. 1 = most important reason for preference; 10 = least important reason

    Article Snippet: Tysabri (natalizumab), developed by Biogen, is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active RRMS.

    Techniques:

    Mean importance of reasons for preference of natalizumab SC related to administration. HCP healthcare professional, SC subcutaneous. 1 = most important reason for preference; 10 = least important reason for preference

    Journal: Neurology and Therapy

    Article Title: Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom

    doi: 10.1007/s40120-026-00888-1

    Figure Lengend Snippet: Mean importance of reasons for preference of natalizumab SC related to administration. HCP healthcare professional, SC subcutaneous. 1 = most important reason for preference; 10 = least important reason for preference

    Article Snippet: Tysabri (natalizumab), developed by Biogen, is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active RRMS.

    Techniques: